AVITA Medical, Inc.

AVITA Medical, Inc.

RCELNYSE / NASDAQHealthcareSmall cap

$15.62-$0.37 (-2.3%)

Last close · Data as of Nov 20, 2026

Market cap
$134.2M
P/E
-2.8x
EV / EBITDA
-4.1x
Revenue
$71.6M
Net margin
-67.8%
ROCE
676.8%

+306.8% over the last year

AVITA Medical, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+13.2%
3M
+54.8%
6M
+261.6%
1Y
+306.8%
5Y
+4.2%

52-week range

Day change -$0.37 (-2.3%) from $16 to $16 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in RCEL, bought on each weekday since 2021.

News & filings

What AVITA Medical filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernShareholders' equity is negative: liabilities exceed assets.

Strengths (1)

  • The price is 109.6% above its 200-day average, and the 50-day average is above the 200-day.
  • The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
  • Shareholders' equity is negative, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.

Read moreShow less

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

Sector
Healthcare
Shares outstanding
30.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$134.2M
P/E
-2.8x
P/B
-8.1x
EV / EBITDA
-4.1x
EV / Sales
2.4x
P/S
1.9x
52-week high
$17.65
52-week low
$3.27

Profitability

Operating margin
-59.4%
Net margin
-67.8%
EBITDA margin
-57.6%
ROE
291.8%
ROCE
676.8%
ROIC
-179.7%
ROA
-86.2%
Asset turnover
1.27

Growth

Revenue
$71.6M
Revenue growth, 1Y
11.5%
Revenue CAGR, 3Y
27.7%
Net profit growth, 1Y
-21.4%
Free cash flow
-$32.9M

Solvency

Current ratio
0.57
Debt / Equity
-2.77
Debt / Assets
0.82
CFO / Net profit
0.64
Cash / Market cap
7.6%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$71.6M
Cost of revenue$12.8M
Gross profit$58.8M
Operating expenses$101.3M
Research and development$20.8M
Selling, general and administrative$80.5M
Operating income-$42.5M
Interest and other-$6.0M
Pretax income-$48.6M
Tax and other$10.0k
Net income-$48.6M

Revenue and net profit

Revenue grew 11.5% in FY2025; net profit is the dashed line.

AVITA Medical, Inc. revenue and net profit by fiscal year
AVITA Medical, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$34.4M-$26.7M
FY2023$50.1M-$35.4M
FY2024$64.3M-$61.8M
FY2025$71.6M-$48.6M

Cash flows

FY2025: -$31.2M from operations, -$32.9M free after investment (dashed).

AVITA Medical, Inc. operating and free cash flow by fiscal year
AVITA Medical, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$19.1M-$19.6M
FY2023-$38.0M-$39.5M
FY2024-$48.9M-$58.3M
FY2025-$31.2M-$32.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$71.6M+11.5%1Y
EBITDA
-$41.2M
Net profit
-$48.6M
Cash from operations
-$31.2M
Free cash flow
-$32.9M
Revenue CAGR, 3Y
27.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$71.6M-$41.2M-$48.6M-$32.9M291.8%+11.5%-21.4%

Monthly returns

Month-by-month returns of RCEL across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$56.4M
Liabilities$73.0M
Equity-$16.6M
Paid-in capital$394.4M
Retained earnings-$408.4M

Market cap against peers

8 peers: same sector, nearest by size.

  1. CVRx, Inc.$156.0M
  2. AVITA Medical, Inc. (this company)$134.2M

Peers map

Healthcare companies placed by value, growth and quality; RCEL highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. AVITA Medical, Inc. (this company)2.4x

Not shown (no positive earnings and no EV / Sales): TuHURA Biosciences, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
AVITA Medical, Inc.RCELthis company$134.2M-2.8x-8.1x291.8%-4.1x
Korro Bio, Inc.KRRO$161.2M-1.4x3.1x-228.0%-2.2x
CVRx, Inc.CVRX$156.0M—4.0x-135.6%—
Nano-X Imaging Ltd.NNOX$144.1M-1.9x1.0x-53.7%-2.1x
Health Catalyst, Inc.HCAT$143.4M-0.8x0.6x-72.4%-2.6x
TuHURA Biosciences, Inc.HURA$139.5M-4.6x6.8x-145.5%-4.7x
SANUWAVE Health, Inc.SNWV$132.3M11.2x81.7x729.6%7.4x
MaxCyte, Inc.MXCT$131.8M-3.0x0.8x-26.0%-3.2x
The Joint Corp.JYNT$117.3M40.3x7.8x19.3%118.2x
Peer median—-1.4x3.6x-63.0%-2.2x

Year-to-date ROI

RCEL since 1 January, against earlier years.

Historical volatility

RCEL's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

AVITA Medical, Inc. operating margin by fiscal year
AVITA Medical, Inc. operating margin by fiscal year
DateOperating margin
FY2022-79.9%
FY2023-85.1%
FY2024-88.1%
FY2025-59.4%
LineFY2025
Cost of revenueCost Of Revenue$12.8M
Gross profitGross Profit$58.8M
Operating expensesOperating Expense$101.3M
Research and developmentResearch And Development$20.8M
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$114.1M
Pretax incomePretax Income-$48.6M

Learn while you research

Academy chapters picked for AVITA Medical, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →